New Clinical Study Evaluates First Drug to Show Improvement in Subtype of Autism

Published April 26, 2012 in EurekAlert

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

New clinical study evaluates first drug to show improvement in subtype of autism

Filed under: , , , , , ,